Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma

Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas, with generally poor prognosis. Historically, there has been a lack of consensus regarding appropriate therapeutic measures for the disease, with conventional frontline chemotherapies being ut...

Full description

Bibliographic Details
Main Authors: Annabelle L. Rodd, Katherine Ververis, Tom C. Karagiannis
Format: Article
Language:English
Published: SAGE Publishing 2012-01-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.4137/CMO.S8536
id doaj-4b192c6fe1ea4e0ab48239ca82dd6d7d
record_format Article
spelling doaj-4b192c6fe1ea4e0ab48239ca82dd6d7d2020-11-25T03:44:29ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492012-01-01610.4137/CMO.S8536Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell LymphomaAnnabelle L. Rodd0Katherine Ververis1Tom C. Karagiannis2Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas, with generally poor prognosis. Historically, there has been a lack of consensus regarding appropriate therapeutic measures for the disease, with conventional frontline chemotherapies being utilized in most cases. Following promising results obtained in 2009, the methotrexate analogue, pralatrexate, became the first drug to gain US FDA approval for the treatment of refractory PTCL. This antimetabolite was designed to have a higher affinity for reduced folate carrier (RFC) and folylpolyglutamate synthetase (FPGS). RFC is the principal transporter for cell entrance of folates and antifolates. Once inside the cell, pralatrexate is efficiently polyglutamated by FPGS. Pralatrexate has demonstrated varying degrees of efficacy in peripheral T-cell lymphoma, with response rates differing between the multiple subtypes of the disease. While phase III studies are still to be completed, early clinical trials indicate that pralatrexate is promising new therapeutic for PTCL.https://doi.org/10.4137/CMO.S8536
collection DOAJ
language English
format Article
sources DOAJ
author Annabelle L. Rodd
Katherine Ververis
Tom C. Karagiannis
spellingShingle Annabelle L. Rodd
Katherine Ververis
Tom C. Karagiannis
Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
Clinical Medicine Insights: Oncology
author_facet Annabelle L. Rodd
Katherine Ververis
Tom C. Karagiannis
author_sort Annabelle L. Rodd
title Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
title_short Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
title_full Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
title_fullStr Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
title_full_unstemmed Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
title_sort safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral t-cell lymphoma
publisher SAGE Publishing
series Clinical Medicine Insights: Oncology
issn 1179-5549
publishDate 2012-01-01
description Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas, with generally poor prognosis. Historically, there has been a lack of consensus regarding appropriate therapeutic measures for the disease, with conventional frontline chemotherapies being utilized in most cases. Following promising results obtained in 2009, the methotrexate analogue, pralatrexate, became the first drug to gain US FDA approval for the treatment of refractory PTCL. This antimetabolite was designed to have a higher affinity for reduced folate carrier (RFC) and folylpolyglutamate synthetase (FPGS). RFC is the principal transporter for cell entrance of folates and antifolates. Once inside the cell, pralatrexate is efficiently polyglutamated by FPGS. Pralatrexate has demonstrated varying degrees of efficacy in peripheral T-cell lymphoma, with response rates differing between the multiple subtypes of the disease. While phase III studies are still to be completed, early clinical trials indicate that pralatrexate is promising new therapeutic for PTCL.
url https://doi.org/10.4137/CMO.S8536
work_keys_str_mv AT annabellelrodd safetyandefficacyofpralatrexateinthemanagementofrelapsedorrefractoryperipheraltcelllymphoma
AT katherineververis safetyandefficacyofpralatrexateinthemanagementofrelapsedorrefractoryperipheraltcelllymphoma
AT tomckaragiannis safetyandefficacyofpralatrexateinthemanagementofrelapsedorrefractoryperipheraltcelllymphoma
_version_ 1724514710333685760